Elranatamab is a humanized IgG2 bispecific T-cell inducing antibody that targets CD3 and B-cell maturation antigen (BCMA) on the surface of T-cells, resulting in activation of T-cells and the release of a variety of pro-inflammatory cytokines that lead to multiple myeloma cell lysis. It can be used in studies related to relapsed or refractory multiple myeloma (RRMM).
Reinheit:
>99.0%
CAS Nummer:
[2408850-14-4]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
